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offer high potential in regenerative medicine in the cardiovas-
cular system. With the aim of translating the use of a human
stem cell-derived endothelial cell product (hESC-ECP) for
treatment of critical limb ischemia (CLI) in man, we report a
good manufacturing practice (GMP)-compatible protocol
and detailed cell tracking and efficacy data in multiple preclin-
ical models. The clinical-grade cell line RC11 was used to
generate hESC-ECP, which was identified as mostly endothelial
(60% CD31+/CD144+), with the remainder of the subset
expressing various pericyte/mesenchymal stem cell markers.
Cell tracking using MRI, PET, and qPCR in a murine model
of limb ischemia demonstrated that hESC-ECP was detectable
up to day 7 following injection. Efficacy in several murine
models of limb ischemia (immunocompromised/immunocom-
petent mice and mice with either type I/II diabetes mellitus)
demonstrated significantly increased blood perfusion and
capillary density. Overall, we demonstrate a GMP-compatible
hESC-ECP that improved ischemic limb perfusion and
increased local angiogenesis without engraftment, paving the
way for translation of this therapy.
INTRODUCTION
Peripheral arterial disease (PAD) is a common disorder and a major
cause of morbidity and mortality, with 202 million people living with
PAD globally in 2010.1 Themost severely affected patients suffer from
critical limb ischemia (CLI), characterized by rest pain, ulcerations,
and/or gangrene, and have a very poor prognosis, with high rates of
limb amputation and mortality.2 The situation is exacerbated in
diabetes mellitus, which is one of the strongest risk factors for
PAD. PAD is often asymptomatic in patients with diabetes mellitus
due to peripheral neuropathy; thus, they may present later with
more severe disease and an increased risk of amputation.3 Despite
improvements in medical and surgical therapies, a significant portion
of patients with CLI are considered “no option” for revascularization,
and no medical therapy capable of reducing the need for amputation
exists.4 Therefore, novel therapies that promote tissue regenerationM
This is an open access article under thand stimulation of angiogenesis are urgently needed for the treatment
of CLI. Pro-angiogenic, cell-based therapies have significant potential
in the treatment of ischemic disease but have not yet showed a clear
clinical success, with the majority of CLI clinical trials carried out to
date utilizing autologous bone marrow- or peripheral blood-derived
cells in small pilot trials.5,6 A recent meta-analysis of randomized
controlled trials (RCTs) (16 RCTs, involving 774 patients) demon-
strated that cell therapy in CLI is associated with reduced risk of
major amputation.7 However, following reanalysis using placebo-
controlled RCTs, these benefits were no longer significant. This calls
for the need to test for alternative sources of stem cells, expanding to
allogenic approaches. The efficacy of cells generated from pluripotent
stem cells, such as human embryonic stem cell (hESC)-derived
endothelial cells (ECs), has yet to be assessed in the clinic. Several
preclinical studies assessing hESC-EC in murine models of CLI
have demonstrated significant improvements in foot perfusion,
accompanied, and hence possibly partially mediated, by increases in
capillary density within ischemic limbs.8–12 Significantly, a break-
through in the cardiovascular cell therapy field was made in a study
that demonstrated the ability of hESC-cardiomyocytes to substan-
tially engraft and regenerate infarcted non-human primate hearts,13
suggesting powerful regenerative effects of hESC-derived products.
Therefore, a major focus of this field is to translate the use of plurip-
otent cell therapy into the clinic to assess its full potential.
A number of multi-step monolayer protocols have been shown to
generate ECs from human pluripotent stem cells (hPSCs). Whereas
these are excellent tools for investigating differentiation and develop-
ment of EC function, the efficiency of conversion and reliance onolecular Therapy Vol. 26 No 7 July 2018 ª 2018 The Authors. 1669
e CC BY license (http://creativecommons.org/licenses/by/4.0/).
Molecular Therapyxenobiotic reagents limits their clinical application. Even the most
well-defined culture systems require use of animal products, such
as Matrigel and/or fetal bovine serum (FBS), at different stages,14–17
which are not appropriate for clinical translation. The source and
grade of the starting PSC population is also important. Very few
studies have used clinical-grade cells, with research-grade hESC and
human-induced PSC (hiPSC) lines commonly utilized.14–16 To over-
come these hurdles, we have adapted an appropriate protocol from
the Cowan lab14 to provide compatibility for good manufacturing
practice (GMP) and clinical-grade production, starting with the use
of a clinical-grade cell line, RC11.18
We propose that administration of the hESC-EC product (ECP)
derived using this protocol would be suitable for treatment of patients
with CLI by stimulating angiogenesis in the affected limb. The final
cell product, rather than purified ECs, was used, as it was considered
that a further cell-sorting step would hinder GMP-compatible pro-
duction, and it is possible that multiple cell populations contribute
to the beneficial effect of cell administration. The aims of this inves-
tigation were to translate the use of hESC-ECP therapy to the clinic
for CLI by (1) developing a robust, clinical-grade, and GMP-compat-
ible protocol for the generation of hESC-ECP and characterization of
the final cell product; (2) assessing the distribution of hESC-ECP
post-transplantation using detailed imaging studies; and (3) evalu-
ating the efficacy of hESC-ECP in a series of complex models using
immunosuppressed/immunocompetent animals, mice with type I
or type II diabetes mellitus, and transplant of cells either immediately
after ischemia induction (acute ischemia) or after 3 days (established
ischemia).
RESULTS
Endothelial Differentiation of Clinical-Grade hESCs Using
GMP-Compatible Reagents
We first set a product profile requiring that greater than 25% of differ-
entiated cells co-express the mature endothelial markers CD31/
CD144, and less than 0.5% of the final product are double positive
for pluripotent markers SSEA4/TRA1-81 or SSEA3/TRA1-60. As
shown in Figure 1A and summarized in Figure 1B, assessment of
21 independent hESC-ECP preparations, generated using the proto-
col, reproducibly and robustly exceeded our requirements with
60.6% ± 3.0% CD31+/CD144+ cells whereas residual pluripotent cells
were only detected in 3/21 samples, giving amean of <0.01% for either
combination of markers (SSEA4/TRA1-81 or SSEA3/TRA1-60). Of
those 3 samples, the highest proportion of double-positive cells was
0.097% (SSEA3/TRA1-60); in all other cases (18/21), the percentage
was lower than the isotype control. The hESC-ECPs were able to
form tubules on Matrigel (Figure S1B), and this ability, in addition
to CD31/CD144 expression, was not affected by 7 hr (during
transportation) at room temperature on day 7 of the protocol (Fig-
ure S2). hESC-ECPs were subsequently used for in vitro and in vivo
characterization.
To determine the identity of the remaining 40% of cells that were not
double positive for the characteristic endothelial combination of1670 Molecular Therapy Vol. 26 No 7 July 2018CD31/CD144, we assessed expression of a wider panel of surface
markers by fluorescence-activated cell sorting (FACS), with a focus
on mesenchyme, pericyte, and hematopoietic cell markers. On day
8 of differentiation, all cells positive for CD144 were also positive
for CD31; therefore, we assessed combinations of CD144 and addi-
tional markers. All of the additional markers were expressed on either
R95% or on%5% of cells, no bi-modal populations were observed,
and, therefore, markers were scored as positive or negative (Fig-
ure 2A). The pattern of staining fell into 3 groups (Figure 2B):
markers typically observed on less mature endothelial cells and co-
expressed on only CD144-positive cells (e.g., CD34, CD105, and
CD309); MSC and pericyte markers on all cells (e.g., CD73, CD44,
CD90, and CD146); and hematopoietic/earlier progenitors that
were negative on all cells (e.g., CD14, CD45, CD56, and CD133).
Analysis of mRNA from the day 8 population also demonstrated
downregulation of pluripotent-associated genes to similar levels to
those of human umbilical vein endothelial cells (HUVECs). HUVECs
were chosen as a control as they are fetal endothelial cells and there-
fore closer in terms of developmental age to hESC-ECPs than adult
ECs. Expression profiles of endothelial genes also reflected the imma-
ture stage of the hESC-ECP; in hESC-ECP, CD31 and CD144
increased over time (8 days) to levels similar to those in HUVECs,
whereas expression levels of KDR and CD34 increased to levels that
were significantly higher than in HUVECs (Figures 1C and S1A).
As the unmanipulated (non-purified cell product) produced by this
protocol is the one intended for clinical use, the total heterogeneous
cell population was used throughout this study and referred to as
hESC-ECP due to the majority endothelial phenotype. Both the endo-
thelial and non-endothelial (based on CD144 sorting) components of
this heterogeneous population expressed genes associated with angio-
genesis (Figure S10).
Longitudinal Biodistribution of Transplanted hESC-ECPs
It was hypothesized that transplanted hESC-ECPs would be present
and engraft for the duration of the study (day 21). Therefore, long-
term distribution of hESC-ECP was assessed in the first instance
using superparamagnetic iron oxide nanoparticle (SPIO) labeling
of hESC-ECP in combination with MRI. hESC-ECP uptake of
SPIO was optimized to ensure sufficient contrast without affecting
hESC-ECP viability or function (Figure S3). Following injection,
MRI imaging of labeled cells in mice without limb ischemia (LI)
demonstrated a moderate signal suppression due to the presence
of SPIO at the injection site on day 1, which returned to baseline
values by day 7 (Figures 3A and 3B). This did not reach statistical
significance by one-way ANOVA. The liver and spleen were also
imaged as these organs are suitable for T2* mapping and are asso-
ciated with uptake of cells from the circulation and SPIO clearance
(Figure 3C). There was no signal suppression within the liver and a
minor time-dependent suppression of signal within the spleen.
hESC-ECP tracking in nude mice with LI (Figures 3D and 3E)
demonstrated greater signal suppression (30% versus 20%),
which was maintained for longer when compared with unoperated
mice (Figure 3B). Significant signal suppression was evident at 1
and 7 days post-injection versus baseline, with no statistically
Figure 1. Endothelial Differentiation of the Clinical-Grade hESC Line RC11
Differentiated cells analyzed on day 8 of the protocol predominantly co-expressed the endothelial markers CD31 and CD144 with few, if any, detectable residual
pluripotent hESCs. (A) Representative flow cytometric analysis for the endothelial (left panels) and pluripotent markers (middle and right panels) with the appropriate
isotype controls is shown. Cells were pre-gated for viable cells (FSC/SSC; 10,000 events) and doublet exclusion (FSC-A/FSC-H). (B) Day 8 hESC-ECP characteristics
assessed against a target profile determined at the start of the study are shown; n = 21 replicates. (C) qPCR-detected expression of selected pluripotent (NANOG,
OCT4, and SOX2) and endothelial (CD31, KDR, and CD34) genes in differentiated RC11 cells shows the downregulation of pluripotency and acquisition of endothelial
phenotype in comparison to mRNA from human umbilical vein endothelial cells (HUVECs) as a positive control. Data are shown as 2DCt  1,000 compared to the
housekeeping gene b-actin. hESC data are n = 4 biological replicates assayed in triplicate, HUVEC n = 3 in triplicate; *p < 0.05, **p % 0.01, and ***p % 0.001 denote
significance compared to d0; yp < 0.05, yyp % 0.01, and yyyp % 0.001 denote level of significance compared to HUVECs using one-way ANOVA with Tukey’s post
hoc test. All data represent mean ± SEM.
www.moleculartherapy.org
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Figure 2. Extended Surface Marker Analysis of Differentiated RC11 hESC-ECP
An extended panel of surface markers known to be expressed in mesodermal, mesenchymal, hematopoietic, or pericyte differentiation of hESC was also assessed on the
CD144/CD31 population (CD144+) and on those cells not expressing CD144 (CD144). (A) Summaries of the data from 3 biological replicates are shown. (B) Examples of
additional markers demonstrating 3 different patterns of expression are shown. Left panel, only CD144+ cells are positive for another marker (CD105); middle panel, CD144+
and CD144 cells are both positive for other marker (CD73); right panel, CD144+ and CD144 cells are both negative for other marker (CD133). EC, endothelial cell; HSC,
hematopoietic stem cell; MSC, mesenchymal stromal cell; SC, stem cell. All data represent mean ± SEM.
Molecular Therapysignificant differences at days 14 and 21 (Figure 3E). In these
mice, there was no signal suppression within the liver or spleen
(Figure 3F).
Short-Term Biodistribution of Transplanted hESC-ECPs
Because long-term tracking suggested that the hESC-ECP was lost
from the hindlimb within the first week following injection,
detailed, dynamic analysis of cell distribution immediately1672 Molecular Therapy Vol. 26 No 7 July 2018following injection was necessary. In order to track the initial dis-
tribution of hESC-ECP within ischemic hindlimbs of nude mice,
cells were labeled with 18F-FLT and imaged by dynamic positron
emission tomography (PET). We previously determined optimal
hESC-ECP labeling with 18F-FLT19 and showed that this did not
affect hESC-ECP viability, proliferation, or function (Figure S4).
Dynamic PET imaging post-injection of labeled hESC-ECP
detected signal in the mouse hindlimb that dropped rapidly over
Figure 3. Longitudinal Tracking of hESC-ECP in Control and Ischemic Limbs
(A) Representative images of control (without limb ischemia), nude (Crl:CD1-Foxn1nu) mouse limbs post-injection of SPIO-labeled hESC-ECP with dark regions indicating
SPIO-mediated signal suppression (circled), taken from the 2nd echo of a T2* mapping sequence. (B) Quantification of mean T2* relaxation time within the injection site relative
to the contralateral control limb is shown; n = 7. (C) Quantification of mean T2* relaxation time within the liver and spleen is shown; n = 7; zp < 0.05 by one-way ANOVA paired
for signal suppression over time. (D) Representative images of ischemicmouse limbs post-injection of SPIO-labeled hESC-ECP are shown, with dark regions indicating SPIO-
mediated signal suppression (circled), taken from the 2nd echo of a T2*mapping sequence. (E) Quantification of mean T2* relaxation time within the injection site relative to the
contralateral control limb is shown; n = 7; *p < 0.05 versus baseline; by one-way ANOVA paired with post hoc Dunnett’s test. (F) Quantification of mean T2* relaxation time
within the liver and spleen is shown; n = 7. All data represent mean ± SEM.
www.moleculartherapy.orgthe 4 hr scanning period (10, 20, 30, 60, 90, 120, 180, and 240 min;
Figures 4A and 4B). This indicated a significant loss of
transplanted cells from the injection site, with 23.5% ± 2.2% cellretention at 4 hr. These data were corrected for radioactive
decay as well as leakage of free radiotracer from the cells (which
accumulated within the elimination organs; Figure S5A). TheMolecular Therapy Vol. 26 No 7 July 2018 1673
Figure 4. PET, qPCR, and Histological Detection of hESC-ECP within Ischemic Hindlimbs at Early and Late Time Points
(A) Representative average time frames of nude (Crl:CD1-Foxn1nu) mice with hindlimb ischemia up to 4 hr post-injection. *Injection site; zurinary bladder. (B) Estimation of cell
retention within the injection site is shown; n = 5; **p% 0.01, ***p% 0.001, and ****p% 0.0001 versus baseline by one-way ANOVA paired with post hoc Dunnett’s test. (C)
qPCR quantification of human DNA in ischemic hindlimbs harvested at time points corresponding to imaging studies is shown. n = 6; *p < 0.05, **p% 0.01, and ***p% 0.001
versus baseline by one-way ANOVA with post hoc Dunnett’s test. (D) Immunofluorescence for human mitochondria (green) within (i) ischemic muscle 21 days post-injection
(PI), (ii) ischemic muscle 4 hr post-injection, and (iii) human positive control (liver) is shown. Nuclei counterstained with DAPI (blue) are shown; images representative of n = 3.
All data represent mean ± SEM.
Molecular Therapymaximum accumulation of signal within the other measured sites
was 0.28%ID, 99-fold lower than in the elimination organs at 4 hr
(Figure S5B).1674 Molecular Therapy Vol. 26 No 7 July 2018qPCR and Histological Detection of Human Cells
To validate the cell distribution profiles demonstrated using MRI
and PET, nude mice with LI received an intramuscular injection
www.moleculartherapy.orgof hESC-ECP and were sacrificed at time points corresponding to
the imaging studies. The percentage of human cells within each
ischemic hindlimb was calculated at each time point (Figure 4C),
using a standard curve with decreasing human:mouse DNA ratios
(Figure S6). There was no decrease in the presence of human cells
within the first 4 hr post-injection and at 24 hr and 7d hESC-ECP
was still present within the ischemic hindlimb, even if at a reduced
amount (0.7% ± 0.2% [24 hr] and 0.4% ± 0.1% [7d] versus 1.8% ±
0.6% at 0 hr; p < 0.05). At days 14 and 21, human cells were no
longer present within the ischemic hindlimb. Qualitative analysis
of human-specific mitochondrial staining within ischemic muscle
harvested at 21 days post-injection demonstrated no significant
signal compared to positively stained, cell-dense patches of
hESC-ECP in tissue harvested 4 hr post-injection and human con-
trol tissue (Figure 4D).
Intramuscular Injection of hESC-ECP Improves Post-ischemic
Blood Flow Recovery in Immunocompromised and
Immunocompetent Mice
The therapeutic efficacy of hESC-ECP was tested in different mouse
models of acute hindlimb ischemia. We first investigated the efficacy
of hESC-ECP in immunocompromised Crl:CD1-Foxn1nu mice,
which are particularly indicated for xenotransplantation. Laser
Doppler measurement showed reduction of blood flow in ischemic
limb shortly after surgical occlusion of femoral artery, confirming
successful induction of acute LI. Follow-up showed progressive re-
covery of blood flow with significantly higher post-ischemic hemo-
dynamic recovery in hESC-ECP-treated mice (Figures 5A and
S7A). Furthermore, cell-treated mice showed increased capillary
density within ischemic limb muscles 21 days post-surgery, as
demonstrated by immunofluorescent staining (Figures 5B, 5C, and
S7B).
To determine whether hESC-ECP therapy requires an immunocom-
promised host, the same protocol was repeated in immunocompetent
CD1 mice with hindlimb ischemia. hESC-ECP administration
induced a significant improvement in hindlimb blood flow when
compared to control CD1 mice (Figures 5D and S7C). There was
also a significant increase in capillary density within adductor muscles
of hESC-ECP-treated mice compared to controls (Figures 5E, 5F, and
S7D).
hESC-ECP Improves Post-ischemic Blood Flow Recovery in
Diabetic Mouse Models of Hindlimb Ischemia
As the majority of patients with CLI have diabetes mellitus, which
further impairs angiogenesis,20,21 we tested the efficacy of hESC-
ECP in type 1 and type 2 diabetic mouse models. We used strepto-
zotocin-induced (STZ) type 1 diabetic CD1 mice and genetically
modified db/db mice (BKS.Cg-Dock7m+/+LeprdbJ) with type 2 dia-
betes. Laser Doppler assessment of blood flow showed progressive
recovery of blood flow in ischemic hindlimbs injected with hESC-
ECP both in STZ type 1 diabetic mice (Figures 6A and S8A) and
in db/db type 2 diabetic mice (Figures 6D and S8C) compared
with EBM-2-treated controls. Moreover, hESC-ECP increased capil-lary to myofiber number ratio both in STZ mice (Figures 6B and 6C)
and in db/db mice (Figures 6E and 6F) compared with controls.
hESC-ECP increased capillary density per mm2 in STZ mice only
(Figures S8B and S8D).
Comparison of hESC-ECP Efficacy Administered in CD1 Mice 3
Days after Establishment of Ischemia
To get closer to the clinical scenario, in which cell therapies for CLI
involve cell transplant into established ischemic conditions, we inves-
tigated whether hESC-ECPs were still effective when delivered at
3 days post-ischemia induction (Figure 7A). CD1 mice that received
hESC-ECP on day 3 post-ischemia induction showed increased blood
flow recovery (Figures 7B and S9). However, hESC-ECP failed to
improve capillary density at day 21 from surgery (Figures 7C–7E).
DISCUSSION
For the first time, we have developed a GMP-compatible protocol
using clinical-grade cells and have shown that this cell product
consistently stimulates increased recovery of blood perfusion to the
ischemic limb in a number of complementary animal models of
limb ischemia, including in animals with diabetes. Cell tracking ex-
periments demonstrated clearance of transplanted hESC-ECP within
2 weeks post-injection, suggesting a paracrine mechanism of action.
Combined, this study paves the way for translation of this method
into the clinic.
Through the adaptation of previously published methodology,14 we
have developed a GMP-compatible protocol using a quality manage-
ment system that is free from xenobiotic reagents, using methods
that can be simply completed in a clean room environment and
importantly utilizing a clinical-grade hESC line (RC11). Generally,
hESC-EC differentiation protocols have a low efficiency, most usu-
ally between 10% and 30%,22–25 resulting in the need for the final
cell product to be sorted using immunomagnetic beads, which intro-
duces additional regulatory and cost considerations. The highly effi-
cient system reported by Patsch et al.14 relies on a sorting step that
generates 80% PSC-ECs. Our newly adapted protocol presented in
this study results in 60% CD31+/CD144+ cells with <0.05% pluripo-
tent markers; thus, this improvement in endothelial-marker-positive
cells removes the need for cell sorting, improving the translatability
of this cell product. In addition, during this multicenter study, hESC-
ECPs were successfully transported by couriers for 7 hr and 370
miles (from Edinburgh to Bristol) without impairing their function,
which is an important consideration for the translation of this cell
product. Our differentiation method produced a preparation of
endothelial progenitors, in addition to a smaller population of cells
that are not overtly endothelial, expressing markers characteristic
of mesenchymal stromal cells (MSCs) and pericyte lineages.
Pericytes perform a supporting role during angiogenesis and have
been shown to improve reperfusion in murine hindlimb ischemia
previously.26 Therefore, it is possible that both the EC progenitor
population and those expressing MSC and pericyte characteristics
may contribute to the efficacy of this product, although this study
has not assessed this aspect. Overall, the important point to note isMolecular Therapy Vol. 26 No 7 July 2018 1675
Figure 5. hESC-ECP Significantly Increases Post-ischemic Blood Flow Recovery and Capillary Density in Nude Crl:CD1-Foxn1nu and Immunocompetent
CD1 Mouse Model of Hindlimb Ischemia
Foot perfusion was assessed following hindlimb ischemia in immunodeficient (Crl:CD1-Foxn1nu) and immunocompetent mice treated with vehicle (EBM-2, control) or hESC-
ECP. The rate of blood flow recovery was expressed as the ratio of ischemic to contralateral limb blood flow at 0, 7, 14, and 21 days post-treatment for (A) immunodeficient,
p < 0.01, n = 12, correlated outcome analysis and (D) immunocompetentmice, p < 0.01, n = 21, correlated outcome analysis. Representative images demonstrating endothelial
cell (green), muscle (wheat germ agglutinin; red), and nuclear (DAPI; blue) markers in control (top) and hESC-ECP-treated (bottom) adductor muscles from (B) immunodeficient
and (E) immunocompetent mice are shown. Scale bar indicates 100 mm. Capillary density expressed as the ratio of capillaries/muscle fiber in (C) immunodeficient, n = 7,
p < 0.05, Mann-Whitney U test, and (F) immunocompetent mice, n = 12, p < 0.05, Mann-Whitney U test, is shown. All data represent mean ± SEM.
Molecular Therapythat this cell product has shown robust efficacy, and it is intended to
be used as a heterogeneous population for clinical translation. In
addition, this is the first study to describe a fully GMP-compatible1676 Molecular Therapy Vol. 26 No 7 July 2018methodology using clinical-grade cells, which has a high endothelial
differentiation efficiency and the ability to withstand the logistics
required as part of a multicenter project.
Figure 6. hESC-ECP Significantly Increase Post-ischemic Blood Flow Recovery in Type 1 and Type 2 Diabetic Mice
Foot perfusion was assessed following hindlimb ischemia in streptozotocin (STZ)-induced type 1 diabetic CD1 mice and in BKS.Cg-Dock7m+/+LeprdbJ (db/db) type 2
diabetic mice treated with either vehicle (EBM-2; control) or hESC-ECP. Blood flow recovery was expressed as the ratio of ischemic to contralateral blood flow at 0, 7, 14, and
21 days post-treatment for (A) STZ-induced type 1 diabetic mice and (D) db/db type 2 diabetic mice, n = 12, p < 0.001, correlated outcome analysis. Representative images
demonstrating endothelial cell (green), muscle (wheat germ agglutinin; red), and nuclear (DAPI; blue) markers in control (top) and hESC-ECP-treated (bottom) adductor
muscles from (B) STZ-induced type 1 diabetic mice and (E) db/db type 2 diabetic mice are shown. Scale bar indicates 100 mm. (C) Capillary density expressed as the ratio of
capillaries/muscle fiber in STZ-induced type 1 diabetic mice, n = 7, p < 0.001, and (F) db/db type 2 diabetic mice, n = 8, p < 0.001, Mann Whitney U test, is shown. All data
represent mean ± SEM.
www.moleculartherapy.orgThe next component of this study was to assess the retention and dis-
tribution of transplanted hESC-ECP using clinically relevant imaging
techniques, the first of which was the use of SPIO labeling and MRIfor longitudinal tracking. For consistency with previous intervention
studies, the cell product was administered using the standard intra-
muscular cell delivery method (i.e., along and/or near the projectionMolecular Therapy Vol. 26 No 7 July 2018 1677
Figure 7. hESC-ECP Efficacy in CD1 Mice with Established Hindlimb Ischemia
(A) Timescale of induction of hindlimb ischemia and cell therapy in acute and established ischemia models. (B) Blood flow recovery expressed as the ratio of ischemic to
contralateral limb blood flow at 0, 7, 14, and 21 days after surgery in an established ischemiamodel, n = 9, p < 0.01, correlated outcome analysis, is shown. (C) Representative
images demonstrating endothelial cell (green), muscle (wheat germ agglutinin; red), and nuclear (DAPI; blue) markers in adductor muscles are shown. Scale bar indicates
100 mm. (D) Capillary density expressed as the ratio of capillaries/ mm2 and (E) capillaries/muscle fiber in established ischemia, n = 5, p = NS for any comparison, Mann
Whitney U test, is shown. All data represent mean ± SEM.
Molecular Therapy
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www.moleculartherapy.orgof the adductor muscle8,11,12,17,26–29) previously shown to increase
blood flow in the preclinical model of limb ischemia.8,11,12,17,26,28,29
There is molecular evidence of ischemia in the adductor in this model,
although it is likely that studies in patients will require cell injections
at numerous sites.16 First, we demonstrated that retention of cells
within ischemic muscles, in which the SPIO signal was present up
to 7 days post-injection, was enhanced in comparison with healthy
skeletal muscle, which is encouraging for use of cells in the clinical
setting. However, at 14 days, labeled cells were no longer detectable
despite their ability to improve reperfusion and capillary density.
Therefore, with MRI suggesting a fast clearance of hESC-ECP, it
was evident that the early tracking of transplanted hESC-ECP was
vital. Short-term cell tracking was developed using dynamic PET
imaging of 18F-FLT-labeled hESC-ECP. In agreement with our MRI
findings, PET demonstrated a rapid clearance of signal over the first
few hours. In addition, qPCR and histology directly confirmed this
early clearance profile, with the cells no longer detectable by the
14-day time point. These results suggest the prevalence of paracrine
mechanisms behind hESC-ECP induced improvement in foot reper-
fusion. Previous and independent preclinical cell therapy studies28,30
already demonstrate improved perfusion of blood to the ischemic
hindlimb in the absence of direct engraftment of transplanted cells.
However, it should be noted that, in other instances within the heart,
extensive engraftment has been reported after hESC-CM transplanta-
tion.13,31 A strategy to improve the post-transplant survival and
retention of our GMP-compatible cells in the future could utilize
biological matrix or scaffolds, such as the recently published extracel-
lular-matrix-mimicking peptide amphiphile nanomatrix gel.17
To translate hESC-ECP into the clinic, it is imperative to robustly
demonstrate their efficacy in a number of models. To our knowledge,
this is the first preclinical study to demonstrate the efficacy of hESC-
ECP in several clinically relevant models (including type 1 and type 2
diabetes and cell transplant in muscles with established ischemia) in
addition to undertaking detailed cell biodistribution studies. More-
over, another important question this study approached was whether
transplanted hESC-ECP could improve ischemic limb reperfusion in
the presence and absence of an intact immune response. In terms of
translation, it is envisaged that allogenic hESC-ECP therapy will take
place alongside transient immunosuppression of the patient.32 How-
ever, in this study, we demonstrate that hESC-ECP can improve
reperfusion to the ischemic foot and increase the capillary density
within the skeletal muscle in both immunocompromised (nude)
and immunocompetent (CD1) mice. Demonstration of efficacy in
the presence of an intact immune response is encouraging and sug-
gests that it may be possible to deliver these cells in the absence of
immunosuppression in the future. Notably, other clinical trials,
such as the PISCES trial, deliver neural stem cells into the brain in
the absence of immunosuppression and have reported no immuno-
logical or cell-related adverse events.33 The next question to be ap-
proached by this study was whether hESC-ECP could elicit their
beneficial effects when administered during established ischemia,
as opposed to administration in the period immediately after the
LI procedure. This experimental design is currently lacking inmany preclinical studies,8–12 in spite of the fact that, in clinical trials
and practice, hESC-ECP will be transplanted into muscles that are
chronically ischemic. hESC-ECP administered on day 3 significantly
increased reperfusion to the foot by day 21. However, unlike the
other LI experiments, no significant improvement was seen in capil-
lary density. This is perhaps not surprising, as arteriogenesis and
angiogenesis are distinct processes in this model,34 both of which
are important to vascular regeneration.34 In addition, we have
recently published findings using this model to compare the recovery
response in various genotypes, which demonstrated that reperfusion
of blood to the foot does not directly correlate with changes in capil-
lary density in this model.35 Therefore, evaluation of both capillary
density and foot perfusion is important in the preclinical assessment
of cell therapies, although perhaps greater emphasis should be placed
on the latter.
hESC-ECP therapy is also likely to be undertaken in the presence of
diabetes mellitus . Diabetes-induced impairment of angiogenesis has
long been known,20,21 and therefore, we assessed the impact of this
condition on the efficacy of hESC-ECP. In both type I and II diabetes
mellitus, hESC-ECP significantly improved foot reperfusion and
skeletal muscle capillary density. Therefore, this study demonstrates
that our GMP-compatible hESC-ECP can rescue blood flow within
the ischemic limb and improve capillary density in a number of clin-
ically relevant models, suggesting that these cells may prove useful in
humans, warranting further study in the clinical setting.
Whereas there are some cell therapy products, such as PLX PAD
(ClinicalTrials.gov identifier: NCT03006770), under investigation in
phase III clinical trials, there remains no US Food and Drug Admin-
istration (FDA)-approved gene or cell therapy for the treatment of
CLI. This may be, in part, due to the fact that these therapies must
demonstrate an increase in amputation-free survival rather than
other benefits, such as reduction in pain and ulcer healing, in order
to be approved.36 In two recently published retrospective meta-
analyses,7,37 cell therapy studies produced no overall reduction in
limb amputations. The only significant improvement demonstrated
was a decrease in pain score following cell treatment versus placebo.37
The failure of these studies could be attributed to a number of factors,
including an overambitious and imprecise primary endpoint, unde-
fined populations, differing production methods, and/or differing
administration regimens (route, dose, and timing). Increasingly, clin-
ical trials are moving away from intra-arterial and intravenous
administration toward intramuscular injections across as many as
30 sites.38 These refinements are crucial to the progression of the field.
Also, we believe the use of a robust, well-defined pluripotent cell-
derived product may result in more favorable results, and clearly
our study warrants such translation using a well-defined population
of cells. To date, trials of hESC-derived products are underway in
several conditions, including macular degeneration, type I diabetes
mellitus (for re-establishing insulin-secreting beta cells), spinal cord
injury, and heart failure,39 with the limited results published so far
demonstrating their safety.40 Clinical assessment of hESC-ECP in
CLI will be an important step in the field and may offer renewedMolecular Therapy Vol. 26 No 7 July 2018 1679
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applicable to the myocardium post-myocardial infarction.41
Whereas the utility of hESC-ECP and pluripotent cell-derived prod-
ucts offers obvious advantages over multipotent or somatic cells, they
are faced with disadvantages, such as the possible requirement for
immunosuppression and risk of teratoma formation.5 One limitation
of our study is that we are yet to undertake assessment of potential
teratoma formation. Whereas we have demonstrated that cells
expressing pluripotent markers are rare in our final hESC-ECP, tera-
toma or tumor formation assessment is planned before clinical trans-
lation. In addition, all preclinical studies are limited by their relation
to the clinical scenario. However, where possible, we have included
the most relevant models in our study. Future studies using larger an-
imal models will allow for more clinically relevant outcome measures
to be assessed, such as ankle brachial index and transcutaneous
oxygen pressure,42,43 as well as allowing for further optimization of
administration route and dose. It is unlikely that future clinical trials
will inject cells solely into ischemic or non-ischemic areas. Areas with
intermediate levels of ischemia (between healthy and necrotic) are
likely to present better options for cell delivery. Given the difficulties
in targeting such areas in the ischemic mouse hindlimb, we have
limited ourselves to essential proof-of-concept studies. It is antici-
pated that future clinical safety and feasibility studies will address op-
timum route of administration, possibly in patients with no other
treatment options available. Finally, our differentiation protocol has
been validated with other lines, including H9 hESC and an iPSC
line NAS244 (Figures S11 and S12) with similar results. This differen-
tiation is robust and reproducible, and we are now using it as a model
in which to study the role of non-coding RNAs during endothelial
commitment and differentiation. Ultimately though, hESC-ECP
derived from RC11 cells will be the product that we intend to assess
in a first-in-man trial; therefore, we have concentrated our efficacy
and cell-tracking efforts on that clinical-grade hESC line. We are
now considering scale-up in a closed culture system, such as CellStack
or Hyperflask (Corning, USA), and cryopreservation of the product
to ease manufacturing and distribution schedules.
Conclusions
In this study, we present a GMP-compatible hESC-ECP production
protocol, with precise characterization of the cellular subsets, which
we aim to use as a heterogeneous endothelial cell product. Positive
efficacy studies in clinically relevant models of limb ischemia demon-
strate the robust efficacy of our product, with the addition of detailed
cell-tracking studies pointing toward a paracrine mechanism of
action. Efforts should now be focused toward a first-in-man clinical
trial utilizing the results from this study.
MATERIALS AND METHODS
Cell Culture and Endothelial Differentiation
A clinical -grade hESC line, RC11 was used throughout and was
maintained in StemPro complete medium (Life Technologies, UK)
with 20 ng/mL basic fibroblast growth factor (bFGF; R&D Systems,
USA). Cultures were passaged when confluent (every 6 or 7 days)1680 Molecular Therapy Vol. 26 No 7 July 2018using EZPassage disposable stem cell passaging tools. Karyotype
was regularly checked and by Giemsa (G)-band analysis was found
to be normal in all 30 cells examined, excluding more than 10%mosa-
icism at 95% confidence (Cytogenetics Laboratory, UK).
Endothelial differentiation was based on modifications to the method
by Patsch et al.14 A detailed method and reagent list can be found in
Supplemental Information. Briefly, on day 0 one T25cm2 flask was
pre-coated with recombinant human fibronectin (3 mg/cm2; R&D
Systems, USA). RC11 at 80%–100% confluence were harvested using
StemPro Accutase (Life Technologies, UK) and plated onto the coated
surface at between 2 and 4  104 cells/cm2 in mTeSR (Stem Cell
Technologies, UK) with 10 mMY27632 Rho-kinase inhibitor (Tocris,
UK) before overnight incubation.
On day 1, the medium was removed and replaced with N2B27
medium (comprising 250 mL DMEM/F12/GlutaMAX medium +
250 mL CTS Neurobasal medium + 2.5 mL GlutaMAX [100] +
10 mL CTS B27 + 5 mL CTS N2 + 0.5 mL b-mercaptoethanol) and
sterile filtered (all from Life Technologies, UK) supplemented with
7 mM CHIR-99021 (GSK3b inhibitor; Sigma Aldrich, UK) and
25 ng/mL rhBMP4 (R&D Systems, USA). Cultures were left until
day 4 with no further media change. On day 4, medium was removed
and replaced with StemPro-34 SFM (Life Technologies, UK) supple-
mented with 200 ng/mL vascular endothelial growth factor (VEGF)-
165 (R&D Systems, USA) and 2 mM forskolin (Sigma Aldrich, UK).
Medium was changed daily to day 6. On day 6, medium was removed
and adherent cell layers were washed with DPBS and detached using
TrypleExpress (Life Technologies, UK). Washed cells were replated
into fresh, T25, or T75 flasks with no fibronectin or other matrix at
4  104 cells/cm2 in modified EGM-2 medium (EBM-2 + EGM-2
SingleQuots [Lonza, Switzerland] omitting the FBS and VEGF)
supplemented with 1% vol:vol human AB serum (Sigma-Aldrich,
UK or SNBTS) and 50 ng/mL VEGF-165. Medium was removed
and replaced on day 7. On day 8, spent medium was removed and
cells were harvested with Tryple Express for in vitro analysis. If cells
were to be used for in vivo assays, they were not harvested, but flasks
were completely filled with modified EGM-2 without the addition of
VEGF and AB serum for expedited transport on day 7. Cells were
transported in T75 flasks packaged in polystyrene boxes at ambient
temperature by dedicated courier to ensure minimal disruption. On
arrival, medium was removed and replaced with complete modified
EGM-2, including AB serum and VEGF, and flasks incubated
overnight for use on day 8. Cells were assessed for cell number and
viability before use.
Cell Characterization
Cells were analyzed on d0 and d8 using flow cytometry, with the an-
tibodies shown in Supplemental Information, using the BD Canto II
(Becton Dickinson, USA). Data were analyzed with FlowJo software
(FlowJo, USA). Cell counts and viability were performed using the
Cell Countess I system (Life Technologies, UK). Matrigel assays
were performed on day 8 cells45 with 1% AB serum and 50 ng/mL
VEGF-165 included in the substrate and assessed after 3 and 6 hr.
www.moleculartherapy.orgExpression of selected pluripotent and endothelial genes was assessed
by real-time PCR on days 0, 6, and 8 of the differentiation protocol
using the Taqman 7900 (Life Technologies, UK).
Mouse Models of Unilateral Hindlimb Ischemia
All animal experiments were performed in accordance with the
Animals (Scientific Procedures) Act (UK) 1986 and under the
auspices of UKHome Office project and personal licenses held within
University of Bristol/University of Edinburgh facilities.
Surgical procedures were performed under inhaled general anesthesia
(isoflurane) and with appropriate peri-operative analgesic cover
(buprenorphine). Unilateral LI was surgically induced by left femoral
artery occlusion as previously reported.46 This procedure consists of
ligation (6-0 silk suture) at two points and electrocoagulation of the
upper part of the left femoral artery, leaving the femoral vein and
nerve untouched. Mice were maintained for up to 21 days after
surgery.
Cell Administration
hESC-ECP was injected (1 106 cells in three injection sites) into the
ischemic adductor muscle. For the majority of protocols, cells were
delivered in the ischemic muscle immediately after LI induction
(acute treatment model). Engraftment studies were performed in
mice with and without LI (vide infra). To get closer to the clinical sce-
nario in which patients are mainly suffering from chronic ischemia,
part of the efficacy studies were performed in subgroups of CD1
mice, which were subjected to cell therapy at 3 days post-ischemia in-
duction (established ischemia model; vide infra and Figure 7A). In all
aforementioned studies, control groups received the vehicle, EBM-2,
rather than cells.
Post-injection hESC-ECP Engraftment Analyses
To investigate the engraftment of hESC-ECP after intramuscular de-
livery, we combined in vivo short-term dynamic and longitudinal
MRI imaging with qPCR to detect human cells and analyses of
anti-human mitochondria immunofluorescence in the mouse
muscles. Immunocompromised Crl:CD1-Foxn1nu mice (aged 7 or
8 weeks at the time of LI operation; Charles River) were employed
in these experiments.
Longitudinal MRI Tracking of hESC-ECP
MRI was used to assess the long-term (1–21 days) fate of SPIO-
labeled hESC-ECP after injection in murine limb muscles. The proto-
col was developed in mice that had either not undergone surgery or
that had undergone unilateral LI (aforementioned acute ischemia
model). Optimal cell labeling conditions were investigated based on
previously reported methods.47,48 Briefly, 5 mg/mL protamine sulfate
(Sigma-Aldrich, UK) was added to 2.5 mg Fe/mL of SPIO (FeraTrack,
Miltenyi Biotec, Germany) and left to form a complex (15 min; room
temperature). The SPIO-protamine complex solution (10 mL) was
added to a T75 culture flask (Corning, USA) containing approxi-
mately 4  106 on day 7 hESC-ECP and incubated (16 hr). The flask
containing the SPIO-labeled hESC-ECP was then washed twice withDPBS (Lonza, Switzerland) before the cells were harvested using
TrypleExpress (Life Technologies, UK). Cell density was then quan-
tified by hemocytometer and adjusted to 1  106 hESC-ECP/15 mL.
SPIO-labeled hESC-ECP were injected into the adductor muscle at
three sites (total = 1  106 cells in EBM-2). MRI scanning was per-
formed 1, 7, 14, and 21 days after surgery. Mice were anesthetized
with 1.8% isoflurane in oxygen/air (50/50; 1 L/min) and placed in a
cradle (Rapid Biomedical, Rimpar, Germany), with their temperature
maintained at 37C throughout. All MRI experiments were per-
formed using a 7-T horizontal bore nuclear magnetic resonance
(NMR) spectrometer (Agilent Technologies, Yarnton, UK); specific
imaging parameters are detailed in the Supplemental Materials and
Methods. T2* maps were blinded before analysis using in-house soft-
ware (MAPPED V3.4, University of Edinburgh), also described in the
Supplemental Materials and Methods.
Short-Term Dynamic PET Cell Tracking
Dynamic PET allows sensitive tracking of 18F-FLT-labeled
hESC-ECP over shorter timescales (%4 hr). 18F-FLT was prepared
using a standard FASTlab FLT Cassette (GE Healthcare, UK) and
was formulated in 9% ethanol in water. Radiochemical purity was
>99% for 18F-FLT. 18F-FLT-hESC-ECP labeling was carried out as
previously described.19 Labeled hESC-ECPs were then harvested
and suspended in EBM-2 at 1  106 cells/15 mL for immediate
administration.
18F-FLT-labeled hESC-ECP (1  106 cells) were injected into the
adductor muscle at three sites (total = 100–200 kBq/1  106 cells),
after which the surgical wound was closed using interrupted sutures
(4/0 silk) and the animal was placed into the nanoPET/computed to-
mography (CT) scanner. Anesthesia was maintained throughout the
imaging session using isoflurane (1.5%; 0.5:0.5 oxygen/nitrous oxide;
1 L/min). All PET data were acquired using a nanoPET/CT scanner
(Mediso, Hungary). Post-administration of radiolabeled cells, a
240-min whole-body emission scan was obtained followed by a CT
scan. Acquisition, reconstruction, and analysis were performed as
previously described to calculate percentage cell retention.19
qPCR Detection of hESC-ECP in Mouse LI
Mice received unlabeled hESC-ECP (1 106) at 3 injection sites in the
adductor muscle immediately after LI and were culled 0 hr, 4 hr, 24 hr,
7 days, 14 days, or 21 days following surgery. Whole animal carcasses
were snap frozen on dry ice prior to isolation of the entire hindlimb
musculature to limit loss of transplanted hESC-ECP at the early
time points. Entire hindlimb muscle tissue was homogenized and
the DNA extracted by a standard phenol-chloroform protocol. Exper-
imental samples and standardmixtures ofmouse (skeletal muscle) and
human DNA (hESC-ECP) were then run in a paired-qPCR assay
(lightCycler; Roche, Switzerland) by an independent researcher with
human- and mouse-specific primers (Table S1) to determine the per-
centage human cells within each experimental sample. As previously
described,49 known ratios of mouse and hESC-ECP DNA were quan-
tified by qPCR using species-specific primers (Table S1) andMolecular Therapy Vol. 26 No 7 July 2018 1681
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standard curve (Figure S6). Positive (human- and mouse-only
DNA) and negative (assay buffer) controls were also run.
Anti-human Mitochondria Immunofluorescence
To assess the distribution of human cells at early and late time points,
mice were culled 4 hr and 21 days following LI surgery and immedi-
ately after injection of unlabeled hESC-ECP. Whole hindlimb muscle
samples were fixed (10% formalin; 24–48 hr) before being dehydrated
and wax embedded. Muscle sections from 9 levels within each sample,
along with human liver (positive control) and mouse skeletal muscle
(negative control), were selected for the detection of human cells
using an anti-human mitochondria antibody. Briefly, rehydrated
slides were blocked with 10% goat serum and incubated overnight
(4C) with anti-human mitochondria (1/100; MAB1273; Merck
Millipore, USA). Primary antibody was detected with an anti-
mouse-horseradish peroxidase (HRP)-conjugated antibody (1/500;
PO447; Agilent Technologies, USA), and by TSA-Cy3 (1/50;
NEL744; Perkin Elmer, USA). Slides were analyzed on an LSM710
confocal microscope (Zeiss, Germany).
Investigation of the Therapeutic Potential of hESC-ECP in the LI
Setting
The therapeutic potential of hESC-ECP was primarily assessed by
determining the capacity of the cells to induce post-LI blood flow
recovery in the several mouse models mentioned above.
Eight- or nine-week-old CD1 or nude (Crl:CD1-Foxn1nu) female
mice (Charles River, UK) were randomly allocated into treatment
or control groups. Type 1 (T1) diabetes mellitus was induced in 6-
or 7-week-old CD1 female mice using STZ (Sigma-Aldrich, UK), as
described previously.50 STZ was delivered intraperitoneally (i.p.) for
five consecutive days (40 mg kg1 in citrate buffer per day). Fourteen
days after the first STZ injection, glycosuria was measured and only
mice with overt glycosuria entered the protocol. Three months after
the onset of hyperglycemia, mice underwent the LI procedure.
Eleven- or twelve-week-old male db/db mice (BKS Cg-Dock7m +/+
Leprdb/J; Envigo, UK) were used as a type 2 diabetes model. Each
of the above mouse types was used for experiments where cell admin-
istration was performed immediately after LI induction. In addition,
subgroups of CD1 mice (left untouched until surgery time) received
either hESC-ECP or fresh EBM-2 medium at 3 days following arterial
ligation.
In addition to the longitudinal blood flow recovery analyses, the capil-
lary density of the ischemic muscles of the different treatment and
control groups was determined at necroscopy (21 days post-surgery).
Influence of hESC-ECP Administration on Blood Flow in Murine
Hindlimb Ischemia Models
Blood flow in the ischemic and contralateral feet was sequentially
analyzed (30 min and 7, 14, and 21 days after surgery) by color laser
Doppler (Moor, UK) on anesthetized mice (1% isoflurane; 1.5 L/min)
placed on a heating plate at 37C to minimize temperature variations.1682 Molecular Therapy Vol. 26 No 7 July 2018The ratio of blood flow between the ischemic and contralateral foot
was calculated to use as an index of percentage blood flow recovery.
Color laser Doppler scans were quantified by two or three blinded,
independent investigators.
Capillary Density
At 21 days post-ischemia, after the last color laser Doppler analysis,
mice were terminally anesthetized and the abdominal aorta was cannu-
lated to perfuse the hindlimbs with 5 mM EDTA in PBS followed by
10% buffered formalin. The ischemic adductor muscle was harvested,
stored overnight at room temperature (RT) in 4% paraformaldehyde
(PFA), washed in PBS, and incubated in 30% sucrose for 24 hr before
being embedded in optimal cutting temperature compound (OCT).
For analysis of capillary densities, adductor muscle sections were
stained with isolectin B4 (Molecular Probes; I21411; 1:100) to identify
the ECs and wheat germ agglutinin (Thermo Fisher Scientific;
W32466) to stain muscle fiber. Slides were observed under a fluores-
cence microscope (Zeiss Z1 fluorescent microscope). 10 high-power
fields were captured (200), and the number of capillaries andmuscle
fibers per field were counted. Capillary density was expressed in two
ways: (1) capillaries per mm2 of transverse muscle section and
(2) capillary number to myofiber number ratio. Capillary density
quantification was conducted by two investigators blinded to the
treatment groups.
Statistical Analysis
Data are presented as mean ± SEM, and n indicates the number of
animals or experimental repeats that were performed, as indicated
in the figure legends. Statistical analyses, power calculations, and
graphical representations were performed with appropriate software
(GraphPad Prism, GraphPad Software, La Jolla, CA, USA; Stata v.
13, StataCorp, College Station, TX, USA). For statistical comparison,
the following tests were used as indicated in the figure legends: one-
way ANOVA paired; one-way ANOVA with Tukey’s post hoc test;
one-way ANOVA unpaired or paired with post hoc Dunnett’s test;
Mann-Whitney U test; and Student’s t test. The interaction of the
effect of treatment group and time in different tested scenarios was
assessed with analysis of response profiles. Significance level was set
at p < 0.05.
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